News

Filter

Current filters:

None

37 to 46 of 96936 results

Takeda US president quits

21-11-2014

The president of Japanese drug major Takeda Pharmaceutical’s (TYO: 4502) US subsidiary, Douglas Cole,…

BoardroomManagementPharmaceuticalTakeda PharmaceuticalUSA

Highlights from the Jefferies 2014 Global Healthcare Conference

Highlights from the Jefferies 2014 Global Healthcare Conference

21-11-2014

Pharma, biotech and health care companies convened in London this week to update investors at the Jefferies…

ALK AbelloClinigen GroupCubistFinancialGW PharmaceuticalsPeter GeorgePharmaceuticalUK

France negotiates lowest price in Europe for Gilead’s Sovaldi

France negotiates lowest price in Europe for Gilead’s Sovaldi

21-11-2014

The discount negotiated by the French government on hepatitis C drug Sovaldi (sofosbuvir), produced by…

FranceGilead SciencesNephrology and HepatologyPharmaceuticalPoliticsPricingRegulationSovaldi

FDA approves Purdue’s opioid analgesic Hysingla ER

21-11-2014

The US Food and Drug Administration has approved Hysingla ER (hydrocodone bitartrate), an extended-release…

Hysingla ERNeurologicalPharmaceuticalPurdue PharmaUSAZogenixZohydro

Stada Arz and mAbxience to negotiate over adalimumab biosimilar

21-11-2014

German drugmaker Stada Arzneimittel and the biotech specialist mAbxience have agreed to negotiate over…

AbbVieadalimumabAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyHumiraLicensingMabxienceSTADA Arzneimittel

Kissei files for Japanese approval of PA21 for hyperphosphatemia

21-11-2014

Japanese mid-sized drugmaker Kissei Pharmaceutical says that a new drug application for PA21 (development…

FreseniusJapanKissei PharmaceuticalNephrology and HepatologyPA21PharmaceuticalRegulationVelphoroVifor Pharma

Future bleak for Novartis’ panobinostat in relapsed/refractory multiple myeloma, says analyst

21-11-2014

The vote against the recommendation that the US Food and Drug Administration approves Novartis’ panobinostat…

daratumumabelotuzumabFarydakNovartisOncologypanobinostatPharmaceuticalRegulation

Sobi pays $10 million to exercise opt-in right for Elocta

Sobi pays $10 million to exercise opt-in right for Elocta

21-11-2014

Nordic biotech firm Swedish Orphan Biovitrum will exercise its opt-in right to take over final development…

Biogen IdecElocateEloctaFinancialHematologyPharmaceuticalSobiSweden

37 to 46 of 96936 results

Parexel

Parexel

Back to top